Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

ing our Senior Subordinated Notes due 2015. Certain expenses

included in Warner Chilcott Limited's ("WCL") consolidated operating

results are not deducted in arriving at Adjusted EBITDA for Warner

Chilcott Holdings Company III, Limited and its subsidiaries.

WARNER CHILCOTT LIMITED

REVENUE BY PRODUCT

(In millions of U.S. dollars)

(Unaudited)

Quarter Ended Year Ended

Dec-31-07 Dec-31-06 Dec-31-07 Dec-31-06

Oral Contraception ("OC")

LOESTRIN 24 FE $41.6 $21.5 $148.9 $44.2

FEMCON FE 11.6 7.5 32.4 7.5

ESTROSTEP FE 10.1 24.0 70.2 103.0

OVCON 35/50 3.4 5.3 15.5 73.8

Total OC 66.7 58.3 267.0 228.5

Hormone therapy ("HT")

ESTRACE Cream 20.2 17.7 73.1 65.8

FEMHRT 16.4 17.0 63.7 58.7

FEMRING 4.8 3.4 15.5 11.3

ESTRACE Tablets 2.1 2.2 9.7 7.6

FEMTRACE 0.6 1.3 3.8 3.3

Total HT 44.1 41.6 165.8 146.7

Dermatology

DOVONEX 37.9 37.3 145.3 146.9

TACLONEX 29.9 22.4 127.2 60.1

DORYX 31.6 27.1 115.8 102.4

Total Dermatology 99.4 86.8 388.3 309.4

PMDD

SARAFEM 9.2 9.6 37.7
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, and Lee,s ... Code: 0950), a research-based biopharmaceutical company headquartered in ... operations in China , today announced ... WuXi,s Laboratory Testing Division (LTD) will be the exclusive ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, ... Knapp, Wis. The company has added a AS16 Sharples centrifuge to harvest products ... during bacterial or fungal fermentation process development. , The new centrifuge greatly ...
(Date:8/25/2015)... ... 2015 , ... One of the world’s foremost authorities on supply chain risk ... been on a mission for the past two weeks. She’s been scrambling to warn ... the two massive explosions that occurred on August 12 at the Ruihai International Logistics ...
(Date:8/25/2015)... Fla. , Aug. 25, 2015  InformedDNA, ... today that it has been awarded Certification in ... Assurance (NCQA). NCQA is a ... accredits and certifies a wide range of healthcare ... key areas of performance. "Our achievement ...
Breaking Biology Technology:WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3New centrifuge and fermentor expand product development capacity at Vets Plus 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4InformedDNA Achieves NCQA Utilization Management Certification 2
... PARIS, Sept. 7, 2011 Cellectis (Alternext: ... announced that its nuclease production capacity has ... costs. Industrialization of the nuclease manufacturing gives ... commercial subsidiary of Cellectis, the potential to ...
... and OXFORD, England, Sept. 7, 2011 CMC Biologics ... entered into a non-exclusive license agreement providing OBT with ... financial terms of which have not been disclosed, covers ... by OBT. CMC Biologics, CHEF1 cell line development platform ...
... Inc. (Nasdaq: RDEA ) announced today that it ... and Drug Administration (FDA) and successfully reached agreement on the ... plan: the overall size and design of the planned Phase ... proposed for NDA filing, manufacturing plans for both drug substance ...
Cached Biology Technology:Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 3CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 2Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 3Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 5
(Date:8/12/2015)... JOSE, Calif. , Aug. 12, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... recently announced Match-in-Sensor solution, have officially been named ... Alliance. As part of the certification, Synaptics, Natural ... FIDO 1.0 Universal Authentication Framework (UAF) standard and ...
(Date:8/10/2015)... 2015 The latest 364 page report ... of the global border security market . Visiongain ... in 2015. Now: Border security is hard to ... the business critical issue you need to know about - ... objective analysis of how this will impact your company and ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... researcher, please contact the Communications and External Relations staff member ... on ORNL and its research and development activities, please refer ... general media-related question or comment, you can send it to ... fuel pellets . . . Oak Ridge ...
... Spain: The numbers of cycles of preimplantation genetic diagnosis ... 2,700 reported in 2004 (the most recent year for ... screen for a growing number of genetically related conditions, ... the targeted condition are available for transfer and the ...
... that gladdens a mother,s heart also lights up the reward ... in a report that appears in the journal Pediatrics ... out the special mother-infant bond and how it sometimes go ... BCM and Texas Children,s Hospital and a research associate in ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3A baby's smile is a natural high 2
UBC13 Antibody...
... PhosphoPlus™ SAPK/JNK (Thr183/Tyr185) Antibody Kit ... Antibody, Catalog #9251, 200 ul SAPK/JNK ... ul SAPK/JNK Cell Extracts, Catalog #9253, ... Antibody, Catalog #7074, 100 ul Anti-biotin ...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
...
Biology Products: